Legend to Supplementary Figures

**Supplementary Figures 1A-B.** Patient #3-0007 with representative baseline and response scan images (~8 months later). White arrows point to tumor. Panels A and B show baseline and response in representative liver metastases. Baseline and response overall tumor burden by irRECIST was 18.1 cm vs 6.1 cm; respectively, a reduction of 66%.

**Supplementary Figures 2A-D.** Patient #3-0013 with representative baseline and response scan images (~2 months later). White arrows point to tumor. Panels A and B show baseline and response in tail of pancreas mass, while panels C and D show baseline and response in bilateral malignant pleural effusions; respectively. Baseline and response overall tumor burden by irRECIST was 9.0 cm vs 9.9 cm; respectively, an increase of 10%. Note that this patient was taken off study because of clinical PD and PD by RECIST 1.1 criteria.

**Supplementary Figures 3A-D.** Patient #3-0019 with representative baseline and response scan images (~2 months later). White arrows point to tumor. Panels A and B show baseline and response in representative liver metastasis, while panels C and D show baseline and response in pelvic bone metastases; respectively. Baseline and response overall tumor burden by irRECIST was 10.9 cm vs 10.5 cm; respectively, a reduction of 4%. Note that this patient had PD by RECIST 1.1 but had overall clinical symptom improvement with a decrease in CA19-9 from 79.1 to 10.9. Thus, this was consistent with pseudo-tumor progression, and the next subsequent response scan demonstrated continuing decrease of tumor burden by irRECIST to 8.0 cm.
Figure S1A. 3-0007 baseline
Figure S1B. 3-0007 response
Figure S2B. 3-0013 baseline
Figure S2C. 3-0013 response
Figure S2D. 3-0013 response
Figure S3A. 3-0019 baseline
Figure S3B. 3-0019 baseline
Figure S3C. 3-0019 response
Figure S3D. 3-0019 response